Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dimebon in Mild to Moderate Alzheimer's Disease
NCT00377715Phase 2Completed
- Sponsor
- Medivation
- Start
- Sep 2005
- Primary completion
- Aug 2006
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Dimebon with Placebo (2 arms). Primary endpoint: Alzheimer's Disease Assessment Scale - cognitive subscale at 26 weeks. Started Sep 2005; status: completed.
02
Drugs
latrepirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00377715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00377715.